Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

February 28, 2011

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Allison Schwartz

2. Date of Event Requiring Statement (Month/Day/Year)
04/26/2022

3. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [BIO BIOB]

(Last)

(First)

(Middle)

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed (Month/Day/Year)

(Street)

HERCULES, CA 94547

6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Bio-Rad A Common Stock	856	D
Bio-Rad B Common Stock	3,848	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽¹⁾	⁽¹⁾	Bio-Rad A Common Stock	80	$ 0 ⁽⁶⁾	D
Restricted Stock Units	⁽²⁾	⁽²⁾	Bio-Rad A Common Stock	164	$ 0 ⁽⁶⁾	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Bio-Rad A Common Stock	168	$ 0 ⁽⁶⁾	D
Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Bio-Rad A Common Stock	131	$ 0 ⁽⁶⁾	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Bio-Rad A Common Stock	122	$ 0 ⁽⁶⁾	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Allison Schwartz C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547	X

Signatures

/s/ Allison Schwartz		04/28/2022
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	On September 5, 2017, the reporting person was granted 400 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
(2)	On September 4, 2018, the reporting person was granted 410 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
(3)	On September 3, 2019, the reporting person was granted 279 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
(4)	On September 2, 2020, the reporting person was granted 174 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
(5)	On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
(6)	Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.